Search results
Author(s):
Simon Ermakov
,
Melvin Scheinman
Added:
3 years ago
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterised by progressive replacement of the ventricular myocardium by fibrofatty tissue.1 Patients with the disease are predisposed to ventricular arrhythmias, heart failure and sudden cardiac death.
Pathophysiology
ARVC has a strong genetic basis with most disease variants displaying an autosomal dominant…
View more
Author(s):
Jackson J Liang
,
Yasuhiro Shirai
,
Aung Lin
,
et al
Added:
3 years ago
Idiopathic ventricular arrhythmias (VAs) are comprised of ventricular premature depolarisations, non-sustained ventricular tachycardia (VT)and rarely sustained VT, and these typically occur in the absence of structural heart disease. In general, idiopathic VAs tend to have a benign prognosis, although a high burden of VAs can result in left ventricular (LV) systolic dysfunction and cardiomyopathy…
View more
Author(s):
Riyaz Kaba
,
Omar Ahmed
,
Elijah R Behr
,
et al
Added:
1 year ago
Author(s):
Adam J Graham
,
Michele Orini
,
Pier D Lambiase
Added:
3 years ago
Recurrent episodes of ventricular tachycardia (VT) in patients with structural heart disease are associated with increased mortality and morbidity, despite the life-saving benefits of implantable cardiac defibrillators (ICDs).1,2 Because ICD therapies are abortive and do not alter the underlying arrhythmogenic substrate, their reduction becomes important, especially as recurrent shocks can cause…
View more
Author(s):
Venkatesh Ravi
,
Jeffrey Winterfield
,
Jackson J Liang
,
et al
Added:
1 year ago
Author(s):
Roberto Keegan
,
Cynthia Yeung
,
Adrian Baranchuk
Added:
3 years ago
Chagas disease is an important public health problem in Latin America. Almost 25% of the population (approximately 65 million individuals) are at risk of infection and another 6 million people are affected.1 However, migration and globalisation have resulted in the increased presence of Chagas disease worldwide, particularly in the US and Europe.
Chagas disease is caused by a parasite, the…
View more
Author(s):
Sebastiaan RD Piers
,
Katja Zeppenfeld
Added:
3 years ago
Over the last 20 years ventricular tachycardia (VT) ablation has evolved from a treatment modality for selected patients withrecurrent haemodynamically tolerated VT (which can be mapped during ongoing arrhythmia), to a therapeutic option for patients with tolerated and untolerated VT using substrate-based ablation strategies.1 The substrate for VT after myocardial infarction (MI) consists of…
View more
Zero X-ray Ablation
Author(s):
Giuseppe Mascia
,
Marzia Giaccardi
Added:
3 years ago
Article
Author(s):
Irina Suman-Horduna
,
Sonya Babu-Narayan
,
Sabine Ernst
Added:
3 years ago
Catheter ablation has moved from ablation of ‘simple’ substrates like accessory pathways,1 atrioventricular nodal re-entrant tachycardias (AVNRTs)2 and re-entrant or focal tachycardia (of either ventricular or atrial origin)3–5 in recent years to more complex arrhythmias such as atrial or ventricular tachycardia (VT) or fibrillation.6–8 Even patients with complex congenital heart disease that may…
View more
Author(s):
Eyal Nof
,
William G Stevenson
,
Roy John
Added:
3 years ago
Sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) are typically a manifestation of significant structural heart disease and often associated with a high risk of sudden cardiac death. Implantable cardioverter defibrillators (ICDs) remain the mainstay of therapy for prevention of sudden cardiac death associated with these arrhythmias.1 However, ICDs treat the arrhythmia after…
View more